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a  b  s  t  r  a  c  t
Post  hoc  analysis  of  a non-comparative,  prospective,  multicentre,  phase  IIIb study  was  performed  to  com-
pare  efﬁcacy  and  safety  of  anidulafungin  in  elderly  (≥65  years)  versus  non-elderly  (<65  years)  Intensive
Care  Unit  (ICU)  patients  with  candidaemia/invasive  candidiasis  (C/IC).  Adult  ICU  patients  with  con-
ﬁrmed  C/IC  meeting  ≥1  of the  following  criteria  were  enrolled:  post-abdominal  surgery;  solid  tumour;
renal/hepatic  insufﬁciency;  solid  organ  transplantation;  neutropenia;  age  ≥65  years.  Patients  received
anidulafungin  (200  mg  on  Day  1, 100  mg/day  thereafter)  for ≥10  days  followed  by  optional  azole  step-
down  therapy  for  a  total  treatment  duration  of  14–56  days.  The  primary  efﬁcacy  endpoint  was  global
(clinical  and  microbiological)  response  at the end  of  all therapy  (EOT).  Primary  efﬁcacy  analysis  was
performed  in  the  modiﬁed  intent-to-treat  (mITT)  population  (n = 170),  excluding  unknown  and  missing
responses.  In  total,  80  patients  (47.1%)  were  aged  ≥65  years  and  90 (52.9%)  were  aged  <65 years;  the
mean  age  difference  between  the  two groups  was 21.9  years.  Global  success  at EOT  in mITT  patients
was  similar  in  elderly  (68.1%)  and  non-elderly  (70.7%)  patients  (P =  0.719).  However,  global  success  rates
were  signiﬁcantly  lower  in elderly  versus  non-elderly  patients  at 2 and  6  weeks  after  EOT  (P  =  0.045  and
P  =  0.016,  respectively).  Ninety-day  survival  was  signiﬁcantly  lower  (P = 0.006)  for  elderly  (42.8%)  versus
non-elderly  patients  (63.3%).  The  incidence  and proﬁle  of adverse  events  were  similar  in  elderly  and
non-elderly  patients.  Anidulafungin  was  effective  and  safe for  treatment  of C/IC  in  elderly  ICU  patients,
everit
d thedespite  higher  baseline  s
© 2012 Elsevier B.V. an
. IntroductionCandidaemia and other forms of invasive candidiasis remain a
igniﬁcant clinical problem in Intensive Care Unit (ICU) patients
nd are associated with considerable morbidity and mortality [1,2].
 These data were presented in part at the 5th Congress on Trends in Medical
ycology  (TIMM-5), 2–5 October 2011, Valencia, Spain.
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thens,  Greece. Tel.: +30 210 5832 182; fax: +30 210 5832 182.
E-mail  address: gdimop@med.uoa.gr (G. Dimopoulos).
924-8579     ©   2012  Elsevier  B.V.  and  the  International  Society  of  Chemotherapy.
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Open accy  of illness  scores.
 International Society of Chemotherapy. 
A recent report from the international Extended Prevalence of
Infection in the ICU (EPIC) II study showed that patients with can-
didaemia had higher crude ICU mortality rates and longer ICU stays
than patients with bacterial bloodstream infections [1].
Prompt  initiation of antifungal therapy is essential for the
effective management of candidaemia/invasive candidiasis (C/IC).
Treatment guidelines recommend that initial antifungal therapy
should be selected on the basis of the infecting organism and local
Open access under CC BY-NC-ND license.susceptibility patterns [3]. Whilst ﬂuconazole is generally effective
for C/IC, its use may  be limited by the increasing prevalence of Can-
dida spp. with acquired or intrinsic resistance to ﬂuconazole [4].
Depending on which guidelines are referred to, echinocandins are
 ess under CC BY-NC-ND license.
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ow recommended as ﬁrst-line treatment for C/IC in all patients [5]
r, more speciﬁcally, in haemodynamically unstable patients (mod-
rately severe to severely ill), those with prior azole exposure and
or invasive infections caused by Candida krusei or Candida glabrata
3] owing to their excellent activity against invasive Candida spp.,
ncluding azole-resistant strains [6].
Due to more frequent and prolonged treatment in hospital,
specially in the ICU, elderly patients are at a greater risk for oppor-
unistic Candida infections [7,8]. Over the past two decades, the
umber of elderly patients admitted to ICUs has increased [9]. A
ecent, relevant longitudinal study reported that among middle-
ged and older adults, patients aged ≥65 years accounted for almost
0% of ICU admissions [10]. In addition, elderly ICU patients are
ore likely than younger patients to have co-morbid conditions
11,12], particularly renal dysfunction [13], which is associated
ith increased mortality in the ICU [14]. Co-morbidities, together
ith age-associated physiological changes and immunosenes-
ence, make the elderly vulnerable to infection [15].
Although the number of elderly patients admitted to ICUs is
ncreasing [9], our understanding of their treatment needs remains
imited. To our knowledge, no studies have speciﬁcally evaluated
he efﬁcacy of an antifungal agent in elderly ICU patients compared
ith patients <65 years old. A recent phase IIIb trial showed that
nidulafungin was both safe and effective for the treatment of C/IC
n selected populations of ICU patients [16]. Given the paucity of
ata in the elderly, a post hoc analysis of this trial was conducted
o evaluate the efﬁcacy and safety of anidulafungin in elderly (aged
65 years) versus non-elderly (aged <65 years) ICU patients with
/IC. The two age groups were also compared with respect to base-
ine demographics, clinical characteristics and infecting pathogens
n order to better characterise elderly patients with C/IC.
.  Materials and methods
.1.  Trial design
This  was a prospective, phase IIIb, exploratory, open-label,
on-comparative, multinational trial. The study was conducted
n accordance with the Declaration of Helsinki and Good Clin-
cal Practice guidelines and was approved by all appropriate
nstitutional review boards and ethics committees. All patients
ere required to provide written informed consent prior to study
nclusion. The trial was registered on ClinicalTrials.gov (identiﬁer
CT00689338).
.2. Patient population
Adult  ICU patients were eligible if they met  the following
riteria: conﬁrmed C/IC within 96 h before to 48 h after initiation
f study treatment; signs and symptoms of acute fungal infection
ithin 48 h prior to initiating study treatment; and an Acute
hysiology and Chronic Health Evaluation (APACHE) II score of
25. Patients were also required to belong to at least one of the
ollowing subpopulations: post-abdominal surgery; solid tumour;
enal insufﬁciency; hepatic insufﬁciency; solid organ transplan-
ation; neutropenia; and/or aged ≥65 years. Patients who had
eceived antifungals for ≤48 h prior to study entry (with up to
ne echinocandin dose) were eligible, but only if no improvement
ad been recorded. As part of the pre-speciﬁed study design,
he presence of renal/hepatic insufﬁciency was determined by
he investigator according to local guidelines; there were no
re-speciﬁed protocol deﬁnitions.
The key study exclusion criteria were: suspected Candida
steomyelitis, endocarditis, meningitis and/or endophthalmitis;
oor venous access; or known hypersensitivity or contraindicationsntimicrobial Agents 40 (2012) 521– 526
to  anidulafungin, ﬂuconazole or voriconazole. The Candida score
was calculated according to previously published methods [17],
both at study entry or at the time when the ﬁrst blood sample was
withdrawn for blood culture and at the end of all therapy (EOT).
In short, the Candida score was  obtained by assessing speciﬁc risk
factors and assigning a total point value according to the following
scoring system: clinical sepsis (2 points); surgery (i.e. recent
surgery requiring post-operative management; 1 point); total
parenteral nutrition (1 point); and multifocal colonisation (1 point).
2.3. Treatment
Patients received intravenous (i.v.) anidulafungin (200 mg  on
Day 1, 100 mg/day thereafter) for 10–42 days. After completing a
minimum of 10 days of treatment, patients could be switched to
oral voriconazole or ﬂuconazole provided they had two  consecutive
negative blood cultures and resolution of signs and symptoms of
acute invasive fungal infection (IFI). The azole dosage was chosen by
the investigator according to local practice. Treatment (with anidu-
lafungin or step-down azole) was continued for ≥14 days after
the last positive blood/tissue culture and resolution/signiﬁcant
improvement of IFI signs and symptoms. The total maximum treat-
ment duration was 56 days. All patients, including those who failed
therapy, were required to return for follow-up visits at 2 weeks and
6 weeks after EOT.
2.4.  Endpoints
The primary efﬁcacy endpoint was global response at EOT in
the modiﬁed intent-to-treat (mITT) population. Global success was
deﬁned as clinical (i.e. cure or signiﬁcant improvement of C/IC
signs and symptoms) and microbiological success (i.e. eradication
or presumed eradication of Candida spp.). The mITT population was
deﬁned as all patients with a conﬁrmed diagnosis of C/IC who  had
received at least one dose of anidulafungin. Global response was
reported as ‘unknown’ or ‘missing’ in patients with an unknown
or missing clinical response, respectively, and any microbiological
response except failure. Clinical response was  deﬁned as ‘unknown’
in non-evaluable patients [i.e. death (not caused by C/IC), loss to
follow-up or received less than three anidulafungin doses]. Unless
otherwise stated, unknown and missing responses were excluded
from the analysis of global response.
Secondary endpoints included: global response at the end of
i.v. therapy (EOIVT) and at 2 weeks and 6 weeks post EOT; sur-
vival at Day 90; and the incidence of adverse events (AEs) in the
safety population (i.e. patients who  received at least one dose of
anidulafungin).
Antifungal susceptibility testing for baseline isolates was con-
ducted according to standard Clinical and Laboratory Standards
Institute (CLSI) methods and breakpoints [18] (i.e. anidulafungin
non-susceptibility, >2 g/mL; ﬂuconazole resistance, ≥64 g/mL;
and voriconazole resistance, ≥4 g/mL).
2.5.  Data analysis
For  this post hoc analysis, patients were divided into elderly
(aged ≥65 years) and non-elderly (aged <65 years) cohorts. An
exact two-sided 95% conﬁdence interval (CI) was calculated for
the success rate at each time point in each age group. A two-sided
Z-test was  used to determine whether the proportion of successes
differed signiﬁcantly between age groups. The same test was used
to compare both the incidence of deep-tissue Candida infection at
baseline and the incidence of renal insufﬁciency/failure/dialysis at
baseline between groups. Age group comparisons of continuous
variables were mostly performed using the two-sample t-test.
The Wilcoxon rank-sum test was  used to compare the use of
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Table 1
Baseline demographics and clinical characteristics in elderly and non-elderly patients (modiﬁed intent-to-treat population).
Characteristic Elderly patients (≥65 years) (N = 80) Non-elderly patients (<65 years) (N = 90)
Demographic characteristics
Male  [n (%)] 49 (61.3) 52 (57.8)
Mean  age (range) (years) 73.8 (65−89) 51.9 (25−64)
Race [n (%)]
White  76 (95.0) 84 (93.3)
Black  1 (1.3) 0 (0)
Other  (including unspeciﬁed) 3 (3.8) 6 (6.7)
Mean  BMI  (range) (kg/m2)a 25.8 (17.7−37.4) 25.5 (15.4−83.0)
Clinical characteristics
Patient  subgroup [n (%)]
Post-abdominal  surgery 44 (55.0) 46 (51.1)
Renal  insufﬁciency/failure/dialysis 41 (51.3) 26 (28.9)
Solid  tumour 18 (22.5) 27 (30.0)
Hepatic  insufﬁciency 7 (8.8) 20 (22.2)
Neutropenic 3 (3.8) 10 (11.1)
Solid  organ transplant recipient 1 (1.3) 9 (10.0)
Infection  site [n (%)]b
Blood only 46 (57.5) 68 (75.6)
Blood  and other normally sterile site 6 (7.5) 1 (1.1)
Other  normally sterile site only 28 (35.0) 21 (23.3)
Peritoneal  ﬂuid 16 (20.0) 13 (14.4)
Bile  2 (2.5) 2 (2.2)
Pleural  ﬂuid 2 (2.5) 1 (1.1)
Multiple  sites 3 (3.8) 0 (0.0)
Other 5  (6.3) 5 (5.6)
Candida  score [mean (95% CI)]c 3.7 (3.5−4.0) 3.1 (2.8–3.3)
SOFA score [mean (95% CI)]d 8.0 (7.1–8.9) 6.5 (5.6–7.5)
APACHE II score
Mean  (95% CI) 17.8 (16.8–18.8) 14.9 (13.8–16.0)
≤20 [n (%)] 55 (68.8) 73 (81.1)
>20  [n (%)] 25 (31.3) 17 (18.9)
BMI, body mass index; CI, conﬁdence interval; SOFA, Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation.
a Assessed in 78 elderly and 87 non-elderly patients.
b ‘With candidaemia’ was deﬁned as any patient who  had either a Candida bloodstream infection only or a Candida bloodstream infection and a Candida deep-tissue
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ing and most (n = 153) were fully susceptible to anidulafungin,
ﬂuconazole and voriconazole. Two of 96 C. albicans isolates were
not susceptible to both ﬂuconazole and voriconazole, 4 of 27 C.
glabrata were not susceptible to ﬂuconazole, 5 of 21 C. parapsilosisnfection; ‘without candidaemia’ was deﬁned as any patient who had Candida deep
c Using the method described by León et al. [17]; assessed in 78 elderly and 89 n
d Assessed in 79 elderly and 87 non-elderly patients.
oncomitant medications between groups. A 2 test of homo-
eneity of distributions was employed to contrast the overall
istribution of baseline pathogens. Survival data were analysed
sing the Kaplan–Meier method, and the difference between
roups was assessed using the log-rank test.
. Results
.1. Patient population
The  mITT population comprised a total of 170 patients who were
ncluded in the present post hoc analysis. Of these patients, 80
47.1%) were aged ≥65 years and 90 (52.9%) were aged <65 years;
he difference in mean age between the two groups was  21.9 years.
Baseline demographics were very similar between the two  age
roups (Table 1). However, at study entry, elderly patients appeared
o be in worse health than non-elderly patients (mean APACHE II
cores of 17.8 vs. 14.9; P = 0.0002) and to have higher mean organ
ailure scores [mean Sequential Organ Failure Assessment (SOFA)
cores of 8.0 vs. 6.5; P = 0.033]. Elderly patients also had higher
ean Candida scores (3.7 vs. 3.1; P = 0.001), a higher incidence
f deep-tissue infections (42.5% vs. 24.4%; P = 0.012) and a higher
ncidence of renal insufﬁciency/failure/dialysis than non-elderly
atients (51.3% vs. 28.9%; P = 0.003).
Elderly  patients were receiving a median of 12 (range 3–36) con-
omitant medications at baseline, which was similar to non-elderly
atients (median 13, range 2–34; P = 0.649).
In terms of overall distribution of baseline pathogens, Candida
lbicans was the most common single pathogen in both age groups
Fig. 1). Candida glabrata was more common in elderly patientse infection only.
erly patients.
(17.5%  vs. 12.2% in non-elderly patients) and Candida parapsilosis
was more common in non-elderly patients (13.3% vs. 6.3% in elderly
patients). However, there was no signiﬁcant difference in the over-
all distributions of Candida spp. between age groups (P = 0.599).
3.2. Susceptibility testing
A  total of 167 baseline isolates underwent susceptibility test-Fig. 1. Distribution of pathogens at baseline in elderly and non-elderly patients
(modiﬁed  intent-to-treat population). * If a patient had more than one baseline
Candida  spp., they only contributed to the group ‘multiple’ pathogens. The overall
distribution of baseline pathogens did not differ signiﬁcantly between elderly and
non-elderly patients (P = 0.599).
5 al of Antimicrobial Agents 40 (2012) 521– 526
w
c
ﬂ
t
l
≤
3
1
p
a
1
1
a
c
n
2
s
3
a
p
p
i
6
l
i
w
r
t
2
t
T
t
[
t
t
C
(
a
a
r
u
T
G
C24 G. Dimopoulos et al. / International Journ
ere not susceptible to ﬂuconazole and 1 of these 21 was not sus-
eptible to anidulafungin, but all C. krusei were not susceptible to
uconazole. Overall, minimum inhibitory concentrations required
o inhibit 50% and 90% of isolates (MIC50/MIC90 values) for anidu-
afungin, ﬂuconazole and voriconazole were 0.03/0.5, 0.5/8 and
0.015/0.5 g/mL, respectively.
.3. Treatment
The mean overall treatment duration in elderly patients was
8.4 days (median 17.5 days, range 1–49 days) and in non-elderly
atients it was 21.3 days (median 19.5 days, range 1–67 days), with
 mean duration of anidulafungin therapy of 15.6 days (median
4.0 days, range 1–42 days) and 16.3 days (median 14.5 days, range
–42 days), respectively. Of the elderly patients, 57 (71.3%) received
nidulafungin only, whilst 20 (25.0%) were switched to oral ﬂu-
onazole and 3 (3.8%) were switched to oral voriconazole. Of the
on-elderly patients, 55 (61.1%) received anidulafungin only, whilst
4 (26.7%) were switched to oral ﬂuconazole and 11 (12.2%) were
witched to oral voriconazole.
.4.  Efﬁcacy
Global and microbiological success rates at each time point by
ge are shown in Table 2. Global success rates at EOT in mITT
atients were similar in elderly (68.1%) and non-elderly (70.7%)
atients (P = 0.719). When unknown and missing responses were
ncluded as treatment failures, the success rates were 61.3% and
4.4%, respectively (P = 0.667). Global success rates were also simi-
ar at EOIVT. However, global success rates were signiﬁcantly lower
n elderly patients compared with non-elderly patients at the 2-
eek and 6-week post-EOT follow-ups (P = 0.045 and P = 0.016,
espectively). This is largely because more patients achieving global
reatment success at EOT in the elderly patient population (n = 13;
6.5%) died between EOT and the 2-week follow-up than those in
he non-elderly population (n = 5; 8.6%) (P = 0.014 for difference).
hese deaths were all due to non-Candida-related causes. The same
rend was not observed between Week 2 and Week 6 of follow-up
n = 3 (11.1%) vs. n = 5 (10.0%); P = 0.879].
In elderly patients, global success rates at EOT were similar in
hose with and without candidaemia (66.7% and 70.4%, respec-
ively; P = 0.744) and in those with C. albicans and non-C. albicans
/IC, excluding patients with multiple baseline Candida pathogens
68.3% and 72.0%, respectively; P = 0.751). Microbiological success
t EOT in mITT patients was similar (P = 0.833) in elderly (72.0%)
nd non-elderly patients (73.5%) (Table 2); microbiological success
ates were also similar at EOIVT. However, at both post-EOT follow-
p visits, microbiological success rates were signiﬁcantly lower in
able 2
lobal and microbiological success rates in elderly and non-elderly patients (modiﬁed in
Response No. (%) of patients [95% CI] 
Elderly patients (≥65 years) 
Global success
EOT  49/72 (68.1%) [56.0–78.6%] 
EOIVT 51/73 (69.9%) [58.0–80.1%] 
2  weeks after EOT 27/54 (50.0%) [36.1–63.9%] 
6  weeks after EOT 16/44 (36.4%) [22.4–52.2%] 
Microbiological response
EOT  54/75 (72.0%) [60.4–81.8%] 
EOIVT 56/76 (73.7%) [62.3–83.1%] 
2  weeks after EOT 27/54 (50.0%) [36.1–63.9%] 
6  weeks after EOT 16/44 (36.4%) [22.4–52.2%] 
I, conﬁdence interval; EOT, end of all therapy; EOIVT, end of intravenous therapy.
a Patients with missing and unknown global or microbiological responses were excludFig. 2. Kaplan–Meier estimates of survival to Day 90 in elderly and non-elderly
patients  (modiﬁed intent-to-treat population). Day 1 represents the ﬁrst day of
anidulafungin therapy.
elderly patients compared with non-elderly patients (P = 0.045 and
P = 0.016 at 2-week and 6-week post-EOT follow-ups, respectively).
3.5. Survival
Kaplan–Meier curves were produced to illustrate survival to
Day 90 in elderly and non-elderly patients (Fig. 2). The 90-day
Kaplan–Meier survival estimate was  signiﬁcantly lower (P = 0.006)
for elderly patients (42.8%, 95% CI 31.8–53.8%) than non-elderly
patients (63.3%, 95% CI 53.4–73.3%). Death causality was  adjudi-
cated by the investigators. All events of death among patients who
achieved global treatment success at EOT and who died between
EOT and the 2-week follow-up were due to non-Candida-related
causes.
3.6. Safety
Among the 216 patients in the safety population, 100 were
elderly and 116 were non-elderly. A total of 42 and 38 treatment-
related AEs occurred in 12/100 (12.0%) and 21/116 (18.1%)
elderly and non-elderly patients, respectively. Although no serious
treatment-related AEs were reported among elderly patients, four
serious events were reported in the non-elderly patient subpopu-
lation. Among the elderly, no single treatment-related AE occurred
in more than two patients (Table 3). In non-elderly patients, the
most commonly reported treatment-related AE was  an increase in
blood alkaline phosphatase levels (n = 3).
4. DiscussionThe ﬁndings of the present analysis suggest that anidulafungin
is effective for the treatment of C/IC in ICU patients aged ≥65 years.
A high global success rate at EOT, the primary study endpoint, was
tent-to-treat population).a
P-value
Non-elderly patients (<65 years)
58/82 (70.7%) [59.6–80.3%] 0.719
60/84 (71.4%) [60.5–80.8%] 0.830
50/74 (67.6%) [55.7–78.0%] 0.045
39/65 (60.0%) [47.1–72.0%] 0.016
61/83 (73.5%) [62.7–82.6%] 0.833
63/85 (74.1%) [63.5–83.0%] 0.950
50/74 (67.6%) [55.7–78.0%] 0.045
39/65 (60.0%) [47.1–72.0%] 0.016
ed from these analyses.
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Table 3
Most  frequently reported (>1%) treatment-related (due to anidulafungin and/or
azoles)  adverse events in elderly and non-elderly patients (safety population).
Adverse event n  (%)
Elderly patients (≥65
years) (N = 100)
Non-elderly patients
(<65  years) (N = 116)
≥1 adverse event 12 (12.0)  21 (18.1)
Abdominal pain 2  (2.0) 0 (0.0)
ALT increased 2 (2.0) 0 (0.0)
AST increased 2 (2.0) 1 (0.9)
Atrial ﬁbrillation 1 (1.0) 2 (1.7)
Blood ALP increased 0 (0.0) 3 (2.6)
Cholestasis 0 (0.0) 2 (1.7)
Convulsion 0 (0.0) 2 (1.7)
Cytolytic hepatitis 0 (0.0) 2 (1.7)
Diarrhoea 2 (2.0) 1 (0.9)
Erythema 2 (2.0) 2 (1.7)
Hyperbilirubinaemia 2 (2.0) 0 (0.0)
Hyperglycaemia 2 (2.0) 0 (0.0)
Hypotension 2 (2.0) 1 (0.9)
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patients having higher scores for severity of illness (i.e. APACHE II,LT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phos-
hatase.
ocumented in the elderly patient cohort (68.1%), which did not
iffer signiﬁcantly from the rate observed in non-elderly patients
70.7%). A similar outcome was observed when unknown and
issing responses were included in the analysis as treatment
ailures, indicating that the primary observation was robust. This
esult was achieved despite the fact that elderly patients had higher
cores for severity of illness at baseline compared with non-elderly
atients, as reﬂected by their signiﬁcantly higher SOFA, APACHE
I and Candida scores as well as a greater likelihood to have renal
nsufﬁciency/failure/dialysis. Similar outcomes were observed
n elderly patients regardless of whether or not candidaemia
as present and in patients with C. albicans or non-C. albicans
/IC. The microbiological success rate in elderly patients was also
igh (72.0%) and supportive of the primary efﬁcacy ﬁndings. The
bservations from this analysis are of clinical relevance given that,
o our knowledge, no studies speciﬁcally focusing on the treatment
f C/IC in ICU elderly patients have been performed to date.
A  notable ﬁnding from this analysis was that the success rate
mong elderly patients declined over time. At 2 weeks and 6 weeks
ost EOT, the global success rates among elderly patients were
igniﬁcantly lower than the rates observed among non-elderly
atients. These differences can be largely explained by the fact that
igniﬁcantly more elderly (26.5%) than non-elderly (8.6%) patients
ho achieved global treatment success at EOT died between EOT
nd the 2-week follow-up, all due to non-Candida-related causes.
his observation is consistent with previous reports suggesting that
lder age is a signiﬁcant and independent risk factor for mortal-
ty in ICU patients with candidaemia [19,20]. Although the precise
easons for this are unknown, reduced age-related physiological
eserve and diminished host resistance may  be contributing fac-
ors. This possible explanation is supported by the observation that
lderly patients had signiﬁcantly higher mean APACHE II scores,
ean SOFA scores and mean Candida scores as well as a higher
ncidence of renal insufﬁciency/failure/dialysis than non-elderly
atients.
This analysis revealed some subtle differences in the epidemi-
logy of C/IC between elderly and younger patients. Candidaemia
as less common in elderly patients (65%) than in non-elderly
atients (77%), which is consistent with a previous study indicat-
ng that age <65 years is a risk factor for candidaemia [21], and a
etrospective cohort study reported that elderly ICU patients were
ess likely to have bloodstream infections than younger patients
10]. Data from a recent pooled analysis of clinical trial data
ith another echinocandin (micafungin) suggested that patientsntimicrobial Agents 40 (2012) 521– 526 525
with  candidaemia have a higher likelihood of treatment success
with antifungal therapy than those with invasive candidiasis [22].
This may, in turn, have been a contributing factor to the poorer
outcomes observed in older patients (≥70 years) in the same study
[22]. In contrast, in the present study, the rates of global success
were similar in patients with (67%) and without candidaemia (70%)
and are supportive of the efﬁcacy of anidulafungin in deep-seated
infection as well as in candidaemia.
Although  there were some numerical differences in the base-
line distribution of Candida spp. between elderly and non-elderly
patients, the overall distribution did not differ signiﬁcantly
between age groups. Candida albicans was  the predominant single
pathogen in both patient cohorts, accounting for ≥55% of base-
line pathogens both in elderly and non-elderly patients. Candida
glabrata was the second most common single aetiological agent
in elderly patients (17.5%) but was less common in non-elderly
patients (12.2%). An increased prevalence of C. glabrata infections
appears to be associated with older age, as has been documented
in several large-scale surveillance studies [23]. Furthermore, in at-
risk patients, C. glabrata has a high mortality rate [24,25]. Since
current treatment guidelines recommend the use of echinocandins
for patients with C. glabrata infections because of emerging azole
resistance [3,5], the current observations suggest that echinocan-
dins may  provide better coverage of potential pathogens in this age
group. Among the 167 baseline isolates that underwent suscepti-
bility testing, an unusually high rate of ﬂuconazole resistance was
observed among C. parapsilosis.
Anidulafungin was  well tolerated by elderly patients despite the
fact that they were receiving multiple concomitant medications in
addition to study treatment. There were no marked differences in
the incidence of AEs in elderly patients compared with non-elderly
patients. No serious AEs were observed in the elderly patient cohort.
Anidulafungin is currently the only available echinocandin for
which no dose adjustments are required for renal and hepatic
impairment and it has no known drug–drug interactions [26,27].
These properties may  have contributed to the excellent tolerability
proﬁle documented in the present analysis and should be consid-
ered when selecting treatment for elderly ICU patients who are
often receiving multiple medications and who commonly present
with multiple organ failure.
The  present analysis was post hoc and was  not part of the orig-
inal study protocol; the ﬁndings reported herein should therefore
be viewed as exploratory only. A further limitation of the present
analysis was  that no multivariate analyses were performed on
factors determining treatment response and patient survival. How-
ever, a formal multivariate analysis of this study is in progress
and will be reported in full at a later date. It would also be of
interest to analyse efﬁcacy outcomes according to the underly-
ing disease (i.e. renal or hepatic insufﬁciency, solid tumour, etc.);
however, patients commonly belonged to one or more subpopu-
lations, which would limit the ability to interpret these results. A
particular strength of the present analysis was  that almost one-
half of the study population was elderly, which presented a unique
opportunity to compare demographic differences and treatment
efﬁcacy between age groups in the setting of a prospective clinical
trial.
5. Conclusions
In conclusion, anidulafungin was effective and safe for the treat-
ment of C/IC in elderly ICU patients (aged ≥65 years), despite theseSOFA), higher Candida scores, greater likelihood of organ failure
and greater likelihood of invasive candidiasis at baseline. Fur-
thermore, the higher incidence of C. glabrata, which is associated
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